What is the value of third-line chemotherapy in advanced gastroesophageal cancer? A 5-year retrospective analysis at a single center.
Justina Yick Ching LamSu Pin ChooDavid Wai-Meng TaiIain Bee Huat TanChee Kian ThamWen Hsin KooSimon Yew Kuang OngSoo Fan AngClarinda Wei Ling ChuaDawn Qingqing ChongPatrick Tze Hern TeoChristabel Jing Zhi LeeSamuel Cheng En EeMatthew Chau Hsien NgPublished in: Asia-Pacific journal of clinical oncology (2019)
The benefit of using non-cross resistant second-line regimens as third-line chemotherapy was small with moderate toxicity. Newer agents such as nivolumab or TAS-102 or clinical trial may be preferred.